Updated

AbbVie's migraine treatment franchise scored a significant win, prompting analysis of whether the pharmaceutical giant represents a compelling buy given its status as a dividend king. The development adds to AbbVie's efforts to diversify revenue streams beyond its legacy Humira franchise. The report weighed the migraine franchise's growth potential against broader questions about AbbVie's pipeline and competitive positioning in specialty pharmaceuticals.